Article
Oncology
Guillaume Virbel, David G. Cox, Anne Olland, Pierre-Emmanuel Falcoz, Clara Le Fevre, Roland Schott, Delphine Antoni, Georges Noel
Summary: Stereotactic body radiotherapy (SBRT) with a 60-Gy schedule in 8 fractions is an effective and well-tolerated treatment for patients with lung oligometastases from any solid primary tumor. It provides favorable clinical outcomes in terms of local control, progression-free survival, overall survival, and toxicity.
FRONTIERS IN ONCOLOGY
(2022)
Review
Medicine, General & Internal
Dongjie Chen, Man Zhao, Xiaoyong Xiang, Jun Liang
Summary: This study compared the efficacy and safety of percutaneous local tumor ablation (LTA) and stereotactic body radiotherapy (SBRT) for early-stage non-small cell lung cancer (NSCLC). The results showed that LTA and SBRT had similar overall survival (OS), progression-free survival (PFS), and locoregional progression (LP). However, SBRT was superior to LTA in OS for tumors >2 cm.
CHINESE MEDICAL JOURNAL
(2022)
Article
Oncology
Kazuhiko Hayashi, Osamu Suzuki, Hiroya Shiomi, Hitoshi Ono, Akira Setoguchi, Masataka Nakai, Erina Nakanishi, Shotaro Tatekawa, Naoko Ose, Takero Hirata, Keisuke Tamari, Yuji Seo, Soichiro Funaki, Fumiaki Isohashi, Shinichi Shimizu, Yasushi Shintani, Kazuhiko Ogawa
Summary: This study evaluated the effectiveness and safety of CyberKnife for the treatment of metastatic lung tumors using SABR with a central high dose. The results showed that SABR with a central high dose using CyberKnife is effective in controlling local lesions with acceptable toxicity.
Article
Oncology
Joe Y. Chang, Reza J. Mehran, Lei Feng, Vivek Verma, Zhongxing Liao, James W. Welsh, Steven H. Lin, Michael S. O'Reilly, Melenda D. Jeter, Peter A. Balter, Stephen E. McRae, Donald Berry, John Heymach, Jack A. Roth
Summary: Long-term results from the revised STARS trial showed that survival after SABR is non-inferior to VATS L-MLND for operable stage IA NSCLC. SABR remains promising for such cases, with multidisciplinary management strongly recommended.
Review
Oncology
Xiaoli Liu, Alexander Chi
Summary: Immunotherapy has revolutionized the treatment of metastatic NSCLC. Combining SBRT with immunotherapy is recognized as a promising treatment option. However, the most optimal approach for this combination remains controversial, and further exploration is needed.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Shuri Aoki, Hiroshi Onishi, Masataka Karube, Naoyoshi Yamamoto, Hideomi Yamashita, Yoshiyuki Shioyama, Yasuo Matsumoto, Yukinori Matsuo, Akifumi Miyakawa, Haruo Matsushita, Hitoshi Ishikawa
Summary: This retrospective study aimed to assess the efficacy and safety of stereotactic body radiotherapy (SBRT) and carbon ion radiotherapy (CIRT) in elderly patients with non-small-cell lung cancer (NSCLC) using Japanese multicenter data. The study found that SBRT and CIRT showed similar survival and local control rates in elderly patients, but CIRT was associated with a lower incidence of radiation pneumonitis.
Article
Oncology
Lichao Huang, Jingmin Bai, Yanyang Zhang, Zhiqiang Cui, Zhizhong Zhang, Jiwei Li, Jinyuan Wang, Xinguang Yu, Zhipei Ling, Baolin Qu, Longsheng Pan
Summary: Stereotactic radiotherapy using CyberKnife is an effective and safe treatment option for residual, recurrent, and metastatic intracranial hemangiopericytomas. Long-term follow-up is necessary for monitoring tumor control and any potential metastasis.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Yuhei Miyasaka, Shuichiro Komatsu, Takanori Abe, Nobuteru Kubo, Naoko Okano, Kei Shibuya, Katsuyuki Shirai, Hidemasa Kawamura, Jun-ichi Saitoh, Takeshi Ebara, Tatsuya Ohno
Summary: The study compared oncologic outcomes after CIRT and SBRT for early-stage NSCLC and found that CIRT showed superior overall survival and local control compared to SBRT. These results were validated by propensity score-adjusted analyses, demonstrating a positive efficacy profile of CIRT in the management of early-stage NSCLC.
Review
Oncology
Xiao-Yao Feng, Jing Li, Ao-Mei Li, Sheng-Hua Jing, Xi-Xu Zhu, Zhen Wang
Summary: This study retrospectively analyzed the safety and efficacy of SBRT for recurrent and oligometastatic STS. The results showed that SBRT is a safe and effective treatment, and histological grade influences local control and survival.
WORLD JOURNAL OF SURGICAL ONCOLOGY
(2022)
Review
Oncology
Guillaume Virbel, Clara Le Fevre, Georges Noel, Delphine Antoni
Summary: Stereotactic body radiation therapy (SBRT) is an effective and safe treatment for lung metastases, particularly in oligometastatic patients with localized disease involving one to three organs. This review summarized the recent progress and evaluation results of radiotherapy for pulmonary metastasis in the past five years.
Article
Oncology
Percy Lee, Billy W. Loo Jr, Tithi Biswas, George X. Ding, Issam M. El Naqa, Andrew Jackson, Feng-Ming Kong, Tamara LaCouture, Moyed Miften, Timothy Solberg, Wolfgang A. Tome, An Tai, Ellen Yorke, X. Allen Li
Summary: Based on the evaluation of published experiences with SBRT, a steep dose-response relationship exists with high rates of durable local control for early-stage non-small cell lung cancer when physical doses of 43-50 Gy are delivered.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2021)
Article
Oncology
Ezgi Oymak, Ozan Cem Guler, Cem Onal
Summary: This study explored the impact of liver metastasis volume on treatment outcomes in breast cancer patients receiving stereotactic body radiotherapy (SBRT). The findings suggest that SBRT is an effective and safe treatment option for oligometastatic breast cancer patients, showing excellent local control and promising survival rates. Patients with smaller tumors demonstrated better overall survival, highlighting the effectiveness of local treatment in this group.
STRAHLENTHERAPIE UND ONKOLOGIE
(2022)
Article
Medicine, General & Internal
Baiqiang Dong, Xuan Zhu, Runzhe Chen, Qing Wu, Jia'nan Jin, Lin Wang, Yujin Xu, Ming Chen
Summary: This study examines the relationship between peripheral blood inflammation parameters and overall survival (OS) and progression-free survival (PFS) in early-stage non-small cell lung cancer patients treated with stereotactic body radiotherapy (SBRT). The results indicate that derived neutrophil-lymphocyte ratio (dNLR) and C-reactive protein (CRP) are independently associated with worse OS, and higher serum levels of post-treatment CRP are associated with inferior PFS. These findings can help guide nursing care and treatment decisions for individual patients.
Article
Oncology
Ran Zhang, Yanling Guo, Yujie Yan, Yuanjun Liu, Yaoyao Zhu, Jingjing Kang, Fangjuan Li, Xiaojiang Sun, Ligang Xing, Yaping Xu
Summary: This study compared survival outcomes and toxicities between patients with clinically diagnosed early-stage lung cancer or biopsy-proven early-stage non-small cell lung cancer, demonstrating the rationality of stereotactic body radiotherapy (SBRT) as a local treatment option for early-stage lung cancer patients. The results showed no significant difference in terms of local control and overall survival between patients with pathologic results versus patients with no pathologic results after propensity score matching (PSM) analysis.
FRONTIERS IN ONCOLOGY
(2021)
Article
Immunology
Pu Zhou, Diangang Chen, Bo Zhu, Wei Chen, Qichao Xie, Yali Wang, Qiulin Tan, Bibo Yuan, Xuejiao Zuo, Changlin Huang, Hongfan Zhu, Guanghui Li
Summary: The study found that the diversity of TCR repertoire and PD-L1 expression in the TME increased significantly after SBRT, with the most enriched term in gene ontology analysis being immune response genes. Although SBRT induced neo-mutation of genes in tumor cells, it did not increase the burden of tumor mutation in tissues. TME showed complex immune cell changes and infiltration, with expression of immune-regulating factors like CXCL10, CXCL16, IFNs, and IFN receptors.
FRONTIERS IN IMMUNOLOGY
(2021)